Integrating genetics and health data to discover common drug effects on cancer and Alzheimer's disease

项目概要/摘要 大多数中年以上的美国人都在服用一种或多种常见药物，这些药物可能隐藏着 对他们随后患癌症或阿尔茨海默病等主要健康后果的风险产生影响。发现 这种药物作用可以改善疾病预防，并提供药物再利用的机会。一 达到这一目的的方法是跟踪人们服用每种常见药物的结果，如健康记录所示。 记录数据。虽然健康数据在规模和细节上都在增长，但它是嘈杂和不完整的。迫切需要 从现有数据源中发现药物作用的新方法。我们提出了新的系统方法 通过建立健康记录模型来评估药物与癌症或阿尔茨海默病的关联。一 创新的概念是我们的平行努力挖掘独立的遗传学数据。我们假设药物的副作用 可以通过分析药物的原始用途和副作用之间共享的病理过程来预测 影响疾病。分析健康状况与癌症或痴呆症之间共有病因的证据，我们 将检验这个假设。我们努力从独立的健康数据中系统地发现药物作用， 遗传学将强化我们的方法结合这两种类型的证据也可以允许关键的评估， 对迟发性疾病的推定药物作用。虽然许多数据驱动的研究将结果的评估留给 在未来的工作中，我们将严格的评估纳入我们的方法，作为改进和加强的手段。 他们的发现。 如果成功，我们的发现将改善癌症和神经退行性疾病的临床管理， 高血压病

Project summary/abstract Most Americans past middle age are taking one or more common drugs, and these drugs may have hidden impacts on their subsequent risk of major health outcomes like cancer or Alzheimer's disease. Discovering such drug effects could improve disease prevention and suggest drug repurposing opportunities. One approach to this end is to follow the outcomes of people taking each common drug, as recorded in health records data. While health data is growing in size and detail, it is noisy and incomplete. There is a critical need for new methods to discover drug effects from existing data sources. We propose novel systematic approaches to assess drug-wide association with cancer or Alzheimer's disease by modeling the health record. One innovative concept is our parallel efforts mining independent genetics data. We hypothesize drug side effects can be predicted by analysis of pathological processes shared between the drug's original use and the side effect disease. Analyzing evidence of shared etiology between health conditions and cancer or dementia, we will test this hypothesis. Our efforts to systematically discover drug effects from independent health data and genetics will strengthen our methods. Combining both types of evidence can also allow critical evaluation of putative drug effects on a late-onset disease. While many data-driven studies leave evaluation of the results to future work, we integrate rigorous evaluations into our methods as a means to improve them and strengthen their findings. If successful, our findings c improve clinical management of cancers and neurodegenerative diseases, illnesses of high